Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene's Q4 Revenues, Loss Rise

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Monday that its fourth-quarter revenues increased sharply as its net loss climbed on a change in fair value of derivative instruments related to warrants.

The San Diego-based molecular diagnostics developer brought in total revenues of $163,000 for the three months ended Dec. 31, compared to $34,000 for the fourth quarter of 2011.

Its net loss for the quarter was $6.3 million, or $.43 per share. Trovagene said that the loss was primarily driven by a $4.9 million, or $.33 per share, charge tied to a change in fair value of derivative instruments related to warrants. Its net loss for Q4 2011 was $1.3 million, or $.12 per share.

Trovagene's R&D costs for the quarter nearly doubled to $594,000 from $308,000 year over year, while its SG&A spending climbed to $1 million from $603,000.

For full-year 2012, Trovagene posted revenues of $450,000, up 75 percent from revenues of $257,000 in 2011.

During the year, Trovagene launched its urine-based molecular human papillomavirus test.

Its net loss for the year increased to $11.6 million, or $.89 per share, from $2.3 million, or $.23 per share.

The firm's R&D spending more than doubled to $1.9 million from $910,000, and its general and administrative costs jumped 48 percent to $3.4 million from $2.3 million.

Trovagene finished the year with $10.8 million in cash and cash equivalents.

The firm brought in net proceeds of $4.4 million from a private placement in the fourth quarter. In January it said that it was seeking to raise $6.1 million through a public offering of its stock.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.